标题
Mechanisms of drug resistance in kinases
作者
关键词
-
出版物
EXPERT OPINION ON INVESTIGATIONAL DRUGS
Volume 20, Issue 2, Pages 153-208
出版商
Informa Healthcare
发表日期
2011-01-17
DOI
10.1517/13543784.2011.546344
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Targeting mTOR with rapamycin: One dose does not fit all
- (2011) David A. Foster et al. CELL CYCLE
- New technologies for autoimmune disease monitoring
- (2011) Holden T Maecker et al. Current Opinion in Endocrinology Diabetes and Obesity
- Biochemical Mechanisms of Resistance to Small-Molecule Protein Kinase Inhibitors
- (2010) Ratika Krishnamurty et al. ACS Chemical Biology
- Inhibitors of the Abl kinase directed at either the ATP- or myristate-binding site
- (2010) Doriano Fabbro et al. BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS
- Discovery of a small-molecule type II inhibitor of wild-type and gatekeeper mutants of BCR-ABL, PDGFR , Kit, and Src kinases: novel type II inhibitor of gatekeeper mutants
- (2010) E. Weisberg et al. BLOOD
- Molecular pathogenesis of tyrosine kinase resistance in chronic myeloid leukemia
- (2010) Paul La Rosée et al. CURRENT OPINION IN HEMATOLOGY
- Epidermal growth factor receptor tyrosine kinase inhibitors as first-line treatment in advanced nonsmall-cell lung cancer
- (2010) Rafael Rosell et al. CURRENT OPINION IN ONCOLOGY
- Targeted therapies for advanced thyroid cancer
- (2010) Efisio Puxeddu et al. CURRENT OPINION IN ONCOLOGY
- Standard treatment of Ph+ CML in 2010: how, when and where not to use what BCR/ABL1 kinase inhibitor?
- (2010) Peter Valent EUROPEAN JOURNAL OF CLINICAL INVESTIGATION
- CYP3A activity influences imatinib response in patients with chronic myeloid leukemia: a pilot study on in vivo CYP3A activity
- (2010) Henrik Gréen et al. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
- Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinib
- (2010) N. P. Shah et al. HAEMATOLOGICA
- A Type-II Kinase Inhibitor Capable of Inhibiting the T315I “Gatekeeper” Mutant of Bcr-Abl
- (2010) Hwan Geun Choi et al. JOURNAL OF MEDICINAL CHEMISTRY
- Inhibitors of phosphatidylinositol-3-kinase in cancer therapy
- (2010) Nathan T. Ihle et al. MOLECULAR ASPECTS OF MEDICINE
- Targeting Bcr–Abl by combining allosteric with ATP-binding-site inhibitors
- (2010) Jianming Zhang et al. NATURE
- Kinase inhibitors attract attention as oral rheumatoid arthritis drugs
- (2010) Alisa Opar NATURE REVIEWS DRUG DISCOVERY
- Multifaceted polo-like kinases: drug targets and antitargets for cancer therapy
- (2010) Klaus Strebhardt NATURE REVIEWS DRUG DISCOVERY
- Integrating molecular diagnostics into anticancer drug discovery
- (2010) István Peták et al. NATURE REVIEWS DRUG DISCOVERY
- Computational solutions to large-scale data management and analysis
- (2010) Eric E. Schadt et al. NATURE REVIEWS GENETICS
- Non-ATP competitive protein kinase inhibitors as anti-tumor therapeutics
- (2009) Lindsay O. Kirkland et al. BIOCHEMICAL PHARMACOLOGY
- Acute dasatinib exposure commits Bcr-Abl-dependent cells to apoptosis
- (2009) J. L. Snead et al. BLOOD
- FMS-Like Tyrosine Kinase 3-Internal Tandem Duplication Tyrosine Kinase Inhibitors Display a Nonoverlapping Profile of Resistance Mutations In vitro
- (2009) N. von Bubnoff et al. CANCER RESEARCH
- Equally Potent Inhibition of c-Src and Abl by Compounds that Recognize Inactive Kinase Conformations
- (2009) M. A. Seeliger et al. CANCER RESEARCH
- Clinical pharmacokinetics of tyrosine kinase inhibitors
- (2009) Nielka P. van Erp et al. CANCER TREATMENT REVIEWS
- Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small-Cell Lung Cancers Dependent on the Epidermal Growth Factor Receptor Pathway
- (2009) Kim-Son H. Nguyen et al. Clinical Lung Cancer
- Aurora kinase inhibitors
- (2009) J.J.E.M. Kitzen et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Kinome signaling through regulated protein–protein interactions in normal and cancer cells
- (2009) Tony Pawson et al. CURRENT OPINION IN CELL BIOLOGY
- The road less traveled: modulating signal transduction enzymes by inhibiting their protein–protein interactions
- (2009) Michelle R Arkin et al. CURRENT OPINION IN CHEMICAL BIOLOGY
- Kinase Inhibitors as Potential Therapeutics for Acute and Chronic Neurodegenerative Conditions
- (2009) G. Cuny CURRENT PHARMACEUTICAL DESIGN
- Mechanisms of resistance to FLT3 inhibitors
- (2009) S. Haihua Chu et al. DRUG RESISTANCE UPDATES
- Ruboxistaurin: PKC-β inhibition for complications of diabetes
- (2009) Ronald P Danis et al. EXPERT OPINION ON PHARMACOTHERAPY
- Hybrid Compound Design To Overcome the Gatekeeper T338M Mutation in cSrc#
- (2009) Matthäus Getlik et al. JOURNAL OF MEDICINAL CHEMISTRY
- Microfluidic single cell arrays to interrogate signalling dynamics of individual, patient-derived hematopoietic stem cells
- (2009) Shannon L. Faley et al. LAB ON A CHIP
- FIP1L1-PDGFRα D842V, a novel panresistant mutant, emerging after treatment of FIP1L1-PDGFRα T674I eosinophilic leukemia with single agent sorafenib
- (2009) E Lierman et al. LEUKEMIA
- Triptolide induces cell death independent of cellular responses to imatinib in blast crisis chronic myelogenous leukemia cells including quiescent CD34+ primitive progenitor cells
- (2009) D. H. Mak et al. MOLECULAR CANCER THERAPEUTICS
- A Conserved Salt Bridge in the G Loop of Multiple Protein Kinases Is Important for Catalysis and for In Vivo Lyn Function
- (2009) Rina Barouch-Bentov et al. MOLECULAR CELL
- Novel mutant-selective EGFR kinase inhibitors against EGFR T790M
- (2009) Wenjun Zhou et al. NATURE
- A new screening assay for allosteric inhibitors of cSrc
- (2009) Jeffrey R Simard et al. Nature Chemical Biology
- Selectivity and therapeutic inhibition of kinases: to be or not to be?
- (2009) Kamran Ghoreschi et al. NATURE IMMUNOLOGY
- Somatic EGFR mutations and efficacy of tyrosine kinase inhibitors in NSCLC
- (2009) Helena Linardou et al. Nature Reviews Clinical Oncology
- Imatinib and beyond—exploring the full potential of targeted therapy for CML
- (2009) Alfonso Quintás-Cardama et al. Nature Reviews Clinical Oncology
- Factors underlying sensitivity of cancers to small-molecule kinase inhibitors
- (2009) Pasi A. Jänne et al. NATURE REVIEWS DRUG DISCOVERY
- Cell cycle kinases as therapeutic targets for cancer
- (2009) Silvia Lapenna et al. NATURE REVIEWS DRUG DISCOVERY
- Targeting innate immunity protein kinase signalling in inflammation
- (2009) Matthias Gaestel et al. NATURE REVIEWS DRUG DISCOVERY
- Kinase mutations in human disease: interpreting genotype–phenotype relationships
- (2009) Piya Lahiry et al. NATURE REVIEWS GENETICS
- Anticipating drug resistance in the MAP kinase pathway
- (2009) Ronen Marmorstein Pigment Cell & Melanoma Research
- Conformational disturbance in Abl kinase upon mutation and deregulation
- (2009) R. E. Iacob et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- MEK1 mutations confer resistance to MEK and B-RAF inhibition
- (2009) C. M. Emery et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- KIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patients
- (2009) K. S. Gajiwala et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Protein kinase inhibitors: contributions from structure to clinical compounds
- (2009) Louise N. Johnson QUARTERLY REVIEWS OF BIOPHYSICS
- Mechanisms of resistance to tyrosine kinase inhibitors in chronic myeloid leukemia and recent therapeutic strategies to overcome resistance
- (2009) D. Bixby et al. Hematology-American Society of Hematology Education Program
- Structure-Based View of Epidermal Growth Factor Receptor Regulation
- (2008) Kathryn M. Ferguson Annual Review of Biophysics
- Comparison of the EGFR resistance mutation profiles generated by EGFR-targeted tyrosine kinase inhibitors and the impact of drug combinations
- (2008) Egle Avizienyte et al. BIOCHEMICAL JOURNAL
- Molecular basis explanation for imatinib resistance of BCR-ABL due to T315I and P-loop mutations from molecular dynamics simulations
- (2008) Tai-Sung Lee et al. CANCER
- Discovery of Drug-Resistant and Drug-Sensitizing Mutations in the Oncogenic PI3K Isoform p110α
- (2008) Eli R. Zunder et al. CANCER CELL
- Palomid 529, a Novel Small-Molecule Drug, Is a TORC1/TORC2 Inhibitor That Reduces Tumor Growth, Tumor Angiogenesis, and Vascular Permeability
- (2008) Q. Xue et al. CANCER RESEARCH
- Hepatocyte Growth Factor Induces Gefitinib Resistance of Lung Adenocarcinoma with Epidermal Growth Factor Receptor-Activating Mutations
- (2008) S. Yano et al. CANCER RESEARCH
- Secondary mutations in the kinase domain of the KIT gene are predominant in imatinib-resistant gastrointestinal stromal tumor
- (2008) Toshirou Nishida et al. CANCER SCIENCE
- Structure and dynamic regulation of Src-family kinases
- (2008) J. R. Engen et al. CELLULAR AND MOLECULAR LIFE SCIENCES
- Molecular Basis of Drug Resistance in Aurora Kinases
- (2008) Fiona Girdler et al. CHEMISTRY & BIOLOGY
- Acquired Resistance to Epidermal Growth Factor Receptor Kinase Inhibitors Associated with a Novel T854A Mutation in a Patient with EGFR-Mutant Lung Adenocarcinoma
- (2008) J. Bean et al. CLINICAL CANCER RESEARCH
- EXEL-7647 Inhibits Mutant Forms of ErbB2 Associated with Lapatinib Resistance and Neoplastic Transformation
- (2008) T. Trowe et al. CLINICAL CANCER RESEARCH
- Doing more than just the structure—structural genomics in kinase drug discovery
- (2008) Brian D Marsden et al. CURRENT OPINION IN CHEMICAL BIOLOGY
- Acquired resistance to tyrosine kinase inhibitors during cancer therapy
- (2008) Jeffrey A Engelman et al. CURRENT OPINION IN GENETICS & DEVELOPMENT
- Therapeutic strategies for inhibiting oncogenic BRAF signaling
- (2008) Ensar Halilovic et al. CURRENT OPINION IN PHARMACOLOGY
- Kinase inhibitors as drugs for chronic inflammatory and immunological diseases: progress and challenges
- (2008) Laura L Rokosz et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- Clinical significance of oncogenicKITandPDGFRAmutations in gastrointestinal stromal tumours
- (2008) J Lasota et al. HISTOPATHOLOGY
- T-Cell–Targeted Signaling Inhibitors
- (2008) Jonghwa Won et al. INTERNATIONAL REVIEWS OF IMMUNOLOGY
- Solution Conformations and Dynamics of ABL Kinase-Inhibitor Complexes Determined by NMR Substantiate the Different Binding Modes of Imatinib/Nilotinib and Dasatinib
- (2008) Navratna Vajpai et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Primary and Secondary Kinase Genotypes Correlate With the Biological and Clinical Activity of Sunitinib in Imatinib-Resistant Gastrointestinal Stromal Tumor
- (2008) Michael C. Heinrich et al. JOURNAL OF CLINICAL ONCOLOGY
- Activity of Bosutinib, Dasatinib, and Nilotinib Against 18 Imatinib-Resistant BCR/ABL Mutants
- (2008) Sara Redaelli et al. JOURNAL OF CLINICAL ONCOLOGY
- BCR-ABL mutants spread resistance to non-mutated cells through a paracrine mechanism
- (2008) J Liu et al. LEUKEMIA
- A quantitative analysis of kinase inhibitor selectivity
- (2008) Mazen W Karaman et al. NATURE BIOTECHNOLOGY
- High-throughput kinase profiling as a platform for drug discovery
- (2008) David M. Goldstein et al. NATURE REVIEWS DRUG DISCOVERY
- Activation of tyrosine kinases by mutation of the gatekeeper threonine
- (2008) Mohammad Azam et al. NATURE STRUCTURAL & MOLECULAR BIOLOGY
- Disruption of the EGFR E884–R958 ion pair conserved in the human kinome differentially alters signaling and inhibitor sensitivity
- (2008) Z Tang et al. ONCOGENE
- Commentary: Novel Therapies for Cancer: Why Dirty Might Be Better
- (2008) T. Fojo ONCOLOGIST
- A conserved protonation-dependent switch controls drug binding in the Abl kinase
- (2008) Y. Shan et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP
- (2008) C.-H. Yun et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Overcoming kinase resistance in chronic myeloid leukemia
- (2007) Francis Lee et al. INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now